Angelica sinensis suppresses human lung adenocarcinoma A549 cell metastasis by regulating MMPs/TIMPs and TGF-β1

Oncology Reports

Volumn 27, Issue 2, 2012, Pages 585-593

  Gao, Min ^a   Zhang, Jun Hong ^a   Zhou, Fu Xiang ^a   Xie, Cong Hua ^a   Han, Guang ^a   Fang, Sheng Quan ^b   Zhou, Yun Feng ^a  

^a WUHAN UNIVERSITY   (China)

^b Tumor Hospital of Hubei Province   (China)

Author keywords

Angelica sinensis; Metastasis; MMP 2; MMP 9; Transforming growth factor

Indexed keywords

GELATINASE A; GELATINASE B; HERBACEOUS AGENT; MATRIX METALLOPROTEINASE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1;

ANGELICA SINENSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL ADHESION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG METASTASIS; MATRIX METALLOPROTEINASE 2 GENE; MATRIX METALLOPROTEINASE 9 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADENOCARCINOMA; ANGELICA SINENSIS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; PLANT EXTRACTS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES; TRANSFORMING GROWTH FACTOR BETA1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862964672     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1527     Document Type: Article

References (56)

1. Claude L, Pérol D, Ginestet C, et al: A prospective study on radiation pneumonitis following conformal radiation therapy in non-small cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol 71: 175-181, 2004. (Pubitemid 38521186)
2. Guo GS and Wang H: Effect of angelica sinensis on fibroblast in bleomycin induced pulmonary fibrosis in rats. Wu Han Da Xue Xue Ba (Yi Xue Ban) 28: 560-563, 2007.
3. Liu WM, Xu QY, Lin YH, Ye YQ, Dai L and Liu YL: Study of influence of 25% angelica injection to bleomycin-induced pulmonary fibrosis. Wu Han Da Xue Xue Ba (Yi Xue Ban) 22: 325-327, 2001.
4. Zhong YH, Han G, Zhou YF, Peng M, Xie CH, Zhou FX and Zhang WJ: Protection of Angelica sinensis against radiation-induced pulmonary fibrosis in mice. Zhonghua Yu Fang Yi Xue Za Zhi 2: 105-109, 2007.
5. Li XT, Wang YQ and Fu Nw: Effect of some drugs of promoting blood circulation and removing blood stasis on the pulmonary metastases of mouse hepatoma cells. J Trad Chinese Med 8: 75-77, 1980.
6. Han JQ, Chen YT, Man YY, et al: Clinical study on effect of combined treatment of fuchunpian with radiotherapy on nasopharyngeal carcinoma. Zhongguo Zhong Xi Yi Jie He Za Zhi 15: 710-712, 1995.
7. Yu JG, Hu SK, Li XL, et al: The effect of paeonia rubba 801 on the occurrence of lung metastasis in Walker 256 tumou. Chin J Cancer Res 5: 226-234, 1993.
8. Parks WC and Shapiro SD: Matrix metalloproteinases in lung biology. Respir Res 2: 10-9, 2001. (Pubitemid 34187902)
9. Stamenkovic I: Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200: 448-464, 2003.
10. Brown PD, Bloxidge RE, Stuart NS, Gatter KC and Carmichael J: Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung carcinoma. J Natl Cancer Inst 85: 574-578, 1993. (Pubitemid 23110933)
11. González-Avila G, Iturria C, Vadillo F, Terán L, Selman M and Pérez-Tamayo R: 72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells. Pathobiology 66: 5-16, 1998.
12. Urbanski SJ, Edwards DR, Maitland A, Leco KJ, Watson A and Kossakowska AE: Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 66: 1188-1194, 1992. (Pubitemid 23006167)
13. Mackay AR, Corbitt RH, Hartzler JL and Thorgeirsson UP: Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 50: 5997-6001, 1990. (Pubitemid 20331412)
14. Kodate M, Kasai T, Hashimoto H, Yasumoto K, Iwata Y and Manabe H: Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int 47: 461-469, 1997. (Pubitemid 27280170)
15. Ray JM and Stetler-Stevenson WG: The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 7: 2062-2072, 1994. (Pubitemid 24366302)
16. Apte SS, Olsen BR and Murphy G: The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 270: 14313-14318, 1995.
17. Goldberg GI, Strongin A, Collier IE, Genrich LT and Marmer BL: Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267: 4583-4591, 1992.
18. Brew K, Dinakarpandian D and Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477: 267-283, 2000. (Pubitemid 30119906)
19. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000. (Pubitemid 30123793)
20. Deryugina EI and Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34, 2006. (Pubitemid 43723979)
21. Wiercinska E, Naber HP, Pardali E, van der Pluijm G, van Dam H and Ten Dijke P: The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat 128: 657-666, 2011.
22. Bruna A, Darken RS, Rojo F, et al: High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11: 147-160, 2007. (Pubitemid 46209848)
23. Han G, Zhou YF, Zhang MS, et al: Angelica sinensis down-regulates hydroxyproline and Tgfb1 and provides protection in mice with radiation-induced pulmonary fibrosis. Radiat Res 165: 546-552, 2006.
24. Xie CH, Zhang MS, Zhou YF, et al: Chinese medicine Angelica sinensis suppresses radiation-induced expression of TNF-alpha and TGF-beta1 in mice. Oncol Rep 15: 1429-1436, 2006.
25. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
26. Zhang S, He B, Ge J, et al: Extraction, chemical analysis of Angelica sinensis polysaccharides and antioxidant activity of the polysaccharides in ischemia-reperfusion rats. Int J Biol Macromol 47: 546-550, 2010.
27. Kim SH, Lee SE, Oh H, et al: The radioprotective effects of bu-zhong-yi-qi-tang: a prescription of traditional Chinese medicine. A J Chin Med 30: 127-137, 2002. (Pubitemid 41758928)
28. Yu F: Protective effects of Angelica sinensis polysaccharide on immunological liver injury induced by con-canavalin A in mice. Zhong Yao Cai 32: 1580-1583, 2009.
29. Ye YN, Liu ES, Li Y, et al: Protective effect of polysaccharides-enriched fraction from Angelica sinensis on hepatic injury. Life Sci 69: 637-646, 2001. (Pubitemid 32673622)
30. Liu PJ, Hsieh WT, Huang SH, Liao HF and Chiang BH: Hematopoietic effect of water-soluble polysaccharides from Angelica sinensis on mice with acute blood loss. Exp Hematol 38: 437-445, 2010.
31. Zhang L, Du JR, Wang J, Yu DK, Chen YS, He Y and Wang CY: Z-ligustilide extracted from Radix Angelica Sinensis decreased platelet aggregation induced by ADP ex vivo and arterio-venous shunt thrombosis in vivo in rats. Yakugaku Zasshi 129: 855-859, 2009.
32. Hou YZ, Zhao GR, Yang J, Yuan YJ, Zhu GG and Hiltunen R: Protective effect of Ligusticum chuanxiong and Angelica sinensis on endothelial cell damage induced by hydrogen peroxide. Life Sci 75: 1775-1786, 2004. (Pubitemid 38961800)
33. Cao W, Li XQ, Wang X, et al: A novel polysaccharide, isolated from Angelica sinensis (Oliv.) Diels induces the apoptosis of cervical cancer HeLa cells through an intrinsic apoptotic pathway. Phytomedicine 17: 598-605, 2010.
34. Cao W, Li XQ, Wang X, Li T, Chen X, Liu SB and Mei QB: Characterizations and anti-tumor activities of three acidic polysaccharides from Angelica sinensis (Oliv.) Diels. Int J Biol Macromol 46: 115-122, 2010.
35. Kan WL, Cho CH, Rudd JA and Lin G: Study of the anti-proliferative effects and synergy of phthalides from Angelica sinensis on colon cancer cells. J Ethnopharmacol 120: 36-43, 2008.
36. Cao W, Li XQ, Hou Y, Fan HT, Zhang XN and Mei QB: Structural analysis and anti-tumor activity in vivo of polysaccharide APS-2a from Angelica sinensis. Zhong Yao Cai 31: 261-266, 2008.
37. Tsai NM, Chen YL, Lee CC, et al: The natural compound n-butylidenephthalide derived from Angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. J Neurochem 99: 1251-1262, 2006.
38. Tsai NM, Lin SZ, Lee CC, et al: The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo. Clin Cancer Res 11: 3475-3484, 2005.
39. Cheng YL, Chang WL, Lee SC, et al: Acetone extract of Angelica sinensis inhibits proliferation of human cancer cells via inducing cell cycle arrest and apoptosis. Life Sci 75: 1579-1594, 2004.
40. Shang P, Qian AR, Yang TH, et al: Experimental study of anti-tumor effects of polysaccharides from Angelica sinensis. World J Gastroenterol 9: 1963-1967, 2003. (Pubitemid 37168422)
41. Lau CB, Ho TC, Chan TW and Kim SC: Use of dong quai (Angelica sinensis) to treat peri- or postmenopausal symptoms in women with breast cancer: is it appropriate? Menopause 12: 734-740, 2005. (Pubitemid 41669126)
42. Fidler IJ: The organ microenvironment and cancer metastasis. Differentiation 70: 498-505, 2005.
43. Joo YE, Seo YH, Lee WS, et al: Expression of tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma. Korean J Intern Med 15: 171-178, 2000.
44. Kim MH, Bodenstine TM, Sumerel LA, Rivera AA, Baker AH and Douglas JT: Tissue inhibitor of metalloproteinases-2 improves antitumor efficacy of a replicating adenovirus in vivo. Cancer Biol Ther 5: 1647-1653, 2006.
45. Simeone AM, McMurtry V, Nieves-Alicea R, Saavedra JE, Keefer LK, Johnson MM and Tari AM: TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells. Breast Cancer Res 10: R44, 2008.
46. Gouyer V, Conti M, Devos P, et al: Tissue inhibitor of metallo-proteinase-1 is an independent predictor of prognosis in patients with non-small cell lung carcinoma who undergo resection with curativeintent. Cancer 103: 1676-1684, 2005. (Pubitemid 40490029)
47. Aljada IS, Ramnath N, Donohue K, et al: Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small cell lung cancer. J Clin Oncol 22: 3218-3229, 2004. (Pubitemid 41103676)
48. Bertaux B, Hornebeck W, Eisen AZ and Dubertret L: Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 97: 679-685, 1991.
49. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E and Iwata K: Growth-promoting activity of tissue inhibitor of metalloproteinases- 1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298: 29-32, 1992.
50. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A and Stetler-Stevenson M: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102: 2002-2010, 1998. (Pubitemid 29001847)
51. Li G, Fridman R and Kim HR: Tissue inhibitor of metalloproteinase- 1 inhibits apoptosis of human breast epithelial cells. Cancer Res 59: 6267-6275, 1999. (Pubitemid 30035652)
52. Rhee JS, Diaz R, Korets L, Hodgson JG and Coussens LM: TIMP-1 alters susceptibility to carcinogenesis. Cancer Res 64: 952-961, 2004.
53. Mo W, Brecklin C, Garber SL, et al: Changes in collagenase and TGF-β precede structural alterations in a model of chronic renal fibrosis. Kidney Int 56: 145-153, 1999. (Pubitemid 29300529)
54. Leehey DJ, Song RH, Alavi N and Singh AK: Decreased degradative enzymes in mesangial cells cultured in high glucose media. Diabetes 44: 929-935, 1995.
55. Death AK, Yue DK and Turtle JR: Competitive RT-PCR for measuring metalloproteinase gene expression in humanmesangial cells exposed to a hyperglycemic environment. Biotechniques 27: 512-518, 1999.
56. Abdel Wahab N and Mason RM: Modulation of neutral protease expression in human mesangial cells by hyperglycaemic culture. Biochem J 320: 777-783, 1996. (Pubitemid 27013791)